Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

BACKGROUND: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Virus Erad
Egile Nagusiak: Hill, Andrew, Hughes, Sophie L, Gotham, Dzintars, Pozniak, Anton L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Mediscript Ltd 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892670/
https://ncbi.nlm.nih.gov/pubmed/29682298
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak